|
|
|
American Society of Interventional Pain Physicians News | August 24, 2016
|
|
|
Legislative Session and Capitol Hill Visits - Make Your Voice Heard!
A legislative conference is scheduled for September 7 and 8. To participate in this conference, you must to be in Washington on Tuesday, September 6 in order to attend the 5 pm preparation session. We will have Capitol Hill visits and speeches, etc., on Wednesday morning and afternoon (Sept. 7). We will be preparing you for the presentation on Tuesday evening at 5:00 pm. We will be attending Capitol Hill with speeches in the morning of Wednesday and Capitol Hill visits with individual members of the Congress on Wednesday afternoon. Some appointments may continue through Thursday. If you would like to leave on Wednesday, please do not plan on leaving before 6 pm. If you want to stay, that would be wonderful as visits will continue on Thursday for those who are available to stay.
Each member is expected to visit two senators and one member of Congress for a total of three visits.
ASIPP will book and pay for your room at the Phoenix Park Hotel in Washington, DC. You will be responsible for your own travel expenses.
It is crucial that we have as many people as possible in attendance for this legislative conference. Please block your schedule as soon as possible so that you can attend.
While many of the members and committees are important, we are specifically focusing on the following senators and members.
Click here for the list.
Please let us know as soon as possible if you will be attending so that we can begin making the appointments. Contact Melinda Martin at
[email protected] to RSVP
|
Registration now Open for October Spinal Cord Stimulation Course
Register today to attend the
Spinal Cord Stimulation Comprehensive Review Course and Cadaver Workshop, Oct. 21, 22 in Orlando. Florida.
The hotel for this meeting will be the Caribe Royale. More information on the ASIPP Room Block and meeting brochure will be available soon!
Caribe Royale
8101 World Center Drive
,
Orlando FL 32821
407-238-8000 Direct
800-823-8300 Reservation
Click HERE to Register for the Course
|
ABIPP Certification Made Simple
The American Board of Interventional Pain Physicians (ABIPP) has developed certification programs that recognize accepted levels of knowledge and expertise in the interventional pain management profession, with the goal of improved patient care. Hundreds of qualified physicians have made the commitment to become ABIPP certified. ABIPP is recognized in 11 states. Ten states have no statutes governing specialty boards. Approval is pending in remaining states.
ABIPP is a Specialty Board providing certifications in the following areas:
Board Certification in Interventional Pain Management
Either with ABMS pain medicine board certification or ABMS primary certification only
Competency Certification in:
* Interventional Pain Management
* Regenerative Medicine
* Controlled Substance Management
* Coding, Compliance, and Practice Management
* Fluoroscopic Interpretation and Radiological Safety
* Endoscopic Spinal Decompression
Click HERE to view Pathway to ABIPP Certification
|
Are You Ready for October 2016: Honeymoon is Coming to an End
Order Your Pocket Guide Today!
 October 1, 2016, is coming. Along with it comes the end of the honeymoon period for ICD-10-CM is also coming. It essentially means you have to get ready for proper coding for the upcoming years.
Starting October 1, 2016, you must have a specific diagnosis for each condition you treat and for each procedure you perform.
You don't need to hit the panic button; there is help for preparation. But you should act now!
You can be prepared for the challenges of ICD-10-CM by purchasing the most definitive ICD-10-CM resource for interventional pain physicians.
If you have not already purchased and reviewed the ICD-10-CM for Interventional Pain Management: A Practical Guide, a pocket guide which will fit nicely in your pocket, you should order it immediately, not only for yourself, but for your staff, electronic and hard copy versions.
This exhaustive guide for interventional pain physicians will assist you with numerous intricacies of coding for interventional pain management. If you are not immediately ordering this practice guide, answer the following questions:
1. If you perform caudal epidural injection and cervical interlaminar epidural injection in a cervical and lumbar post surgery syndrome patient, can you use the same code for both procedures and get paid?
2. Can you perform lumbar transforaminal epidural injections at L5 and S1 in a patient with lumbar radiculitis at L5 only?
3. Can you use disc herniation and radiculopathy codes in the same patient in the same region?
If you answer "yes" for any of the above questions, you urgently need to prepare yourself and review these guidance.
Related story:
|
| Listen to August ASIPP Podcast
 In the August ASIPP podcast we'll be talking with Christy Davies of Apex Biologix about the business potential of adding regenerative medicine procedures to your practice. Our news segment has a story about a pain medication showing promise as a treatment for Alzheimer disease, new hope for eliminating opioid tolerance, the pay gap between male and female doctors, and much more. Plus, the health hazards of bagpipes.
|
Obamacare is failing. But there is one way to fix it-commentary
Aetna's pullback from the Affordable Care Act's (ACA) Insurance Exchanges is another bad omen in a growing list.
Throughout the controversial history of Obamacare, Aetna has been a stalwart continuing to voice confidence in the future of the program.
That confidence took an abrupt and sudden turn this week when it cited unsustainable losses as the reason it was cutting back from 15 states to only four. Aetna reported Obamacare losses of $200 million in just the second quarter and more than $430 million since January of 2014. They expect full-year exchange losses of $320 million in 2016 alone.
|
Start Planning NOW! ASIPP to Begin Accepting Abstracts for 2017 Annual Meeting
Registration will be open for Abstract Submissions beginning August 10, 2016.
The American Society of Interventional Pain Physicians will hold its 19th Annual Meeting April 20-22 in Las Vegas at Caesar's Palace.
This year, we will be making significant changes to the Abstract and Poster Sessions. Anyone who submits their Abstract for consideration will be included in the electronic poster presentations. The posters are available to all meeting participants during all bring and meal times.
The Abstract Committee will select the top 25 for publication in Pain Physician and of those 10 will be selected for Abstract presentation and judging during the Annual Meeting. The top 3 will receive cash prizes.
|
Impact of Patent Expiries on the Pain Management Therapeutics Market
A report recently published by Transparency Market Research (TMR), a US-based "provider of syndicated research, customized research, and consulting services," presents a comprehensive overview of the current (2015 data) and projected (2024) pain management therapeutics landscape.
1
According to this report, the market for Global Pain Management Therapeutics amounted to $60.2 trillion in 2015, and anticipated to grow beyond $83 trillion in 2024. Over 52% of the pain management drug market was represented in 2015 -and is projected to be sustained in 2024- by opioids (including oxycodones, hydrocodones, morphine, fentanyl, tramadol) and non-steroidal anti-inflammatory drugs, and followed in descending order by anticonvulsants, antidepressants, anti-migraines and other non-narcotic analgesics.
|
Precision Medicine for Chronic Pain
According to the Institute of Medicine, pain affects more than one-third of all Americans and costs more than $600 billion annually.
1
Specifically, chronic pain, broadly categorized as non-cancer and cancer pain, is notoriously challenging to treat, and its poor management resulting from a "one-size-fits-all" strategy, remains a significant cause of misery with huge socioeconomic costs. The need for new molecular targets to design more effective pain treatments options is evident.
Over the past decade, improved understanding of the genetic underpinning of many diseases have resulted in the explosion of targeted therapies that have paved the way to personalized, and precision medicine.
|
A Path Forward on Medicare Payment Reform for Physician-Administered Drugs
The recent proposal for a large-scale test of payment reforms for Medicare Part B "physician-administered" drugs has generated broad opposition from many patient groups, physician specialty societies and pharmaceutical companies. While many consumer organizations that represent Medicare beneficiaries have expressed support, the future of the proposed reforms is unclear.
Officials at the Centers for Medicare and Medicaid Services (CMS) have stated that the proposal will be modified before moving forward, which we believe is the right response. The core concepts to reform Part B drug payments complement other reforms being implemented by CMS and the private sector. To make these concepts operational, CMS should modify the payment formula changes proposed in Phase 1 to prevent adverse impacts, and develop the pricing-reform ideas in Phase 2 through much more public engagement.
|
Why small and mid-size employers are increasingly opting to pay workers' medical costs directly
Instead of buying a health insurance policy to cover their workers, a growing number of small and midsized companies are opting to pay their employees' medical claims directly, a potentially riskier practice financially called self-insuring, a recent study found.
Between 2013 and 2015, the proportion of midsized companies with 100 to 499 employees that were self-insured increased 19 percent, to 30.1 percent, according to the analysis published in July by the Employee Benefit Research Institute. The percentage of small firms with fewer than 100 employees that self-funded their health plans grew 7 percent, to 14.2 percent, the study found. Meanwhile, self-funding by large companies declined slightly, to 80.4 percent.
|
Occipital Nerve Stimulation for Chronic Migraine: Long-Term Outcomes
Over 40% of patients with intractable chronic migraine who received occipital nerve stimulation treatment experienced long-term clinical benefit, according to a study published in The Journal of Headache and Pain.
1
The study team, led by Dr Sarah Miller of the Institute of Neurology and The National Hospital for Neurology and Neurosurgery in London, examined outcomes for a cohort of 53 patients from a single treatment center after a median follow-up of 42 months. All patients received occipital nerve stimulation implants consisting of bilateral ONS electrodes, leads and an implantable pulse generator between 2007 and 2013.Chronic migraine is defined as more than 15 headache days per month over a 3 month period. While many patients with chronic migraine benefit from medical treatment, 5% either cannot tolerate or prove refractory to evidence-based therapies.
Clinical Pain Advisor
|
Placebos Extending Painkiller Doses
In a review recently published in Pain, Luana Colloca, MD, PhD of the University of Maryland and colleagues advocate for the development of pain management regimens incorporating the use of "dose-extending placebos."
1
In such treatments, inert substances or subclinical doses of medication are interspersed with active treatments, in accordance with reinforcement learning principles.
|
|
|
|
|
|
State Society News
|
|
Physicians Wanted To view or post a job, please go to: http://jobs.asipp.org/home To receive a member discount for posting a job, use member code: 20Member |
|
|
